Endocrine Disorders Clinical Trials
Browse 23 Clinical Trials Across 83 Cities
9 Phase 3 Trials · 205 Clinics
Reviewed by Michael Gill, B. Sc.
23 Clinical Trials Near Me
Top Hospitals for Clinical Trials
National Institutes of Health Clinical Center
Bethesda
3Active Trials
0All Time Trials for
1995First Trial
Children's Hospital & Research Center Oakland
Oakland
3Active Trials
0All Time Trials for
2016First Trial
Top Cities for Clinical Trials
Most Recent Null
Top Treatments for Clinical TrialsClinical Trial
Began Recruiting Date
Phase
Treatment Name
Active Clinical Trials
All Time Trials for
First Recorded Trial
Chronocort
2
2
2021
Lonapegsomatropin
2
2
2020
Crinecerfont
2
2
2020
Abiraterone acetate
2
2
2017
BMN 111
2
2
2016
About The Author
Michael Gill - B. Sc.
First Published: October 11th, 2021
Last Reviewed: November 8th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Relevant Clinical Trials
Top Oncology Trials
Popular Clinical Trials
References1 Savarirayan R, Irving M, Bacino CA, Bostwick B, Charrow J, Cormier-Daire V, Le Quan Sang KH, Dickson P, Harmatz P, Phillips J, Owen N, Cherukuri A, Jayaram K, Jeha GS, Larimore K, Chan ML, Huntsman Labed A, Day J, Hoover-Fong J. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia. N Engl J Med. 2019 Jul 4;381(1):25-35. doi: 10.1056/NEJMoa1813446. Epub 2019 Jun 18. https://pubmed.ncbi.nlm.nih.gov/312695462 Auchus RJ, Buschur EO, Chang AY, Hammer GD, Ramm C, Madrigal D, Wang G, Gonzalez M, Xu XS, Smit JW, Jiao J, Yu MK. Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2014 Aug;99(8):2763-70. doi: 10.1210/jc.2014-1258. Epub 2014 Apr 29. https://pubmed.ncbi.nlm.nih.gov/247800503 Berg C, Meinel T, Lahner H, Yuece A, Mann K, Petersenn S. Diagnostic utility of the glucagon stimulation test in comparison to the insulin tolerance test in patients following pituitary surgery. Eur J Endocrinol. 2010 Mar;162(3):477-82. doi: 10.1530/EJE-09-0824. Epub 2009 Dec 8. https://pubmed.ncbi.nlm.nih.gov/199961994 Savarirayan R, De Bergua JM, Arundel P, McDevitt H, Cormier-Daire V, Saraff V, Skae M, Delgado B, Leiva-Gea A, Santos-Simarro F, Salles JP, Nicolino M, Rossi M, Kannu P, Bober MB, Phillips J 3rd, Saal H, Harmatz P, Burren C, Gotway G, Cho T, Muslimova E, Weng R, Rogoff D, Hoover-Fong J, Irving M. Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies. Ther Adv Musculoskelet Dis. 2022 Mar 21;14:1759720X221084848. doi: 10.1177/1759720X221084848. eCollection 2022. https://pubmed.ncbi.nlm.nih.gov/353424575 Sävendahl L, Battelino T, Brod M, Højby Rasmussen M, Horikawa R, Juul RV, Saenger P; REAL 3 study group. Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial. J Clin Endocrinol Metab. 2020 Apr 1;105(4). pii: dgz310. doi: 10.1210/clinem/dgz310. Erratum in: J Clin Endocrinol Metab. 2020 Dec 1;105(12):. https://pubmed.ncbi.nlm.nih.gov/319178356 Gómez JM, Espadero RM, Escobar-Jiménez F, Hawkins F, Picó A, Herrera-Pombo JL, Vilardell E, Durán A, Mesa J, Faure E, Sanmartí A. Growth hormone release after glucagon as a reliable test of growth hormone assessment in adults. Clin Endocrinol (Oxf). 2002 Mar;56(3):329-34. https://pubmed.ncbi.nlm.nih.gov/119400447 Yuen KC, Frystyk J, Rhoads SA, Bidlingmaier M. Pegvisomant-primed glucagon stimulation test in assessing GH reserve and GH/IGF kinetics in adults suspected of GH deficiency. Pituitary. 2016 Feb;19(1):65-74. https://pubmed.ncbi.nlm.nih.gov/264967678 Sävendahl L, Battelino T, Rasmussen MH, Brod M, Saenger P, Horikawa R. Effective GH replacement with once-weekly somapacitan vs daily GH in children with GHD: 3-year results from REAL 3. J Clin Endocrinol Metab. 2021 Dec 29. pii: dgab928. doi: 10.1210/clinem/dgab928. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/349644589 Radetti G, Wu Z, Elsedfy HH, El Kholy M, Bozzola M, Strasburger CJ. Pegvisomant-primed GH stimulation test. Clin Endocrinol (Oxf). 2008 Jun;68(6):951-6. Epub 2007 Nov 19. https://pubmed.ncbi.nlm.nih.gov/1803132010 Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. J Clin Endocrinol Metab. 2001 Jul;86(7):3304-10. https://pubmed.ncbi.nlm.nih.gov/11443205
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments